当前位置: X-MOL 学术Epidemiol. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CEPI: Driving Progress Toward Epidemic Preparedness and Response.
Epidemiologic Reviews ( IF 5.2 ) Pub Date : 2019-11-01 , DOI: 10.1093/epirev/mxz012
Dimitrios Gouglas , Mario Christodoulou , Stanley A Plotkin , Richard Hatchett

The Coalition of Epidemic Preparedness Innovations (CEPI) was formed in the aftermath of the 2014-15 Ebola outbreak in west Africa to support the development of vaccines that could improve the world's preparedness against outbreaks of epidemic infectious diseases. Since its launch in 2017, CEPI has mobilised over US$ 750 million to support its mission to develop vaccines against agents such as Lassa Virus, Middle East Respiratory Syndrome coronavirus, and Nipah Virus, as well as several rapid response vaccine platforms to accelerate response times to unexpected epidemic threats. CEPI has also played a leading role in fostering institutional partnerships between public-sector and private-sector organisations to optimise allocation of resources for vaccine development against its priority pathogens. CEPI's priorities include diversification of its current vaccine research and development investment portfolio to include additional pathogens, such as Rift Valley Fever and Chikungunya; establishment of technical and regulatory pathways for vaccine development across CEPI's portfolio; development of sustainable manufacturing solutions for vaccine candidates nearing completion of safety and immunogenicity testing in humans; and creation of investigational stockpiles of its vaccine candidates for use in emergency situations. This commentary provides an overview of the global health challenges CEPI was established to address, its achievements to date, and indicates priorities for funding and coordination in the coming years.

中文翻译:

CEPI:推动流行病防备和应对的进展。

在2014-15年西非埃博拉疫情爆发后成立了流行病防范创新联盟(CEPI),以支持疫苗开发,从而可以改善世界对流行病传染病暴发的防范能力。自2017年启动以来,CEPI已筹集超过7.5亿美元来支持其使命,以开发针对诸如Lassa病毒,中东呼吸综合征冠状病毒和Nipah病毒等药剂的疫苗,以及几个快速响应疫苗平台以加快响应时间应对意外的流行病威胁。CEPI在促进公共部门和私营部门组织之间的机构伙伴关系,以针对其主要病原体优化疫苗开发资源分配方面也发挥了领导作用。CEPI' 优先事项包括使其目前的疫苗研发投资组合多样化,以包括其他病原体,例如裂谷热和基孔肯雅热;为整个CEPI产品组合建立疫苗开发的技术和监管途径;为即将完成的人体安全性和免疫原性测试的候选疫苗开发可持续制造解决方案;以及创建用于紧急情况的候选疫苗的研究库存。该评论概述了CEPI为应对全球健康挑战而建立的,迄今为止所取得的成就,并指出了未来几年的资金和协调重点。如裂谷热和基孔肯雅热;为整个CEPI产品组合建立疫苗开发的技术和监管途径;为即将完成的人体安全性和免疫原性测试的候选疫苗开发可持续制造解决方案;以及创建用于紧急情况的候选疫苗的研究库存。该评论概述了CEPI为应对全球健康挑战而建立的,迄今为止所取得的成就,并指出了未来几年的资金和协调重点。如裂谷热和基孔肯雅热;为整个CEPI产品组合建立疫苗开发的技术和监管途径;为即将完成的人体安全性和免疫原性测试的候选疫苗开发可持续制造解决方案;以及创建用于紧急情况的候选疫苗的研究库存。该评论概述了CEPI为应对全球健康挑战而建立的,迄今为止所取得的成就,并指出了未来几年的资金和协调重点。以及创建用于紧急情况的候选疫苗的研究库存。该评论概述了CEPI为应对全球卫生挑战而建立的,迄今为止所取得的成就,并指出了未来几年的资金和协调重点。以及创建用于紧急情况的候选疫苗的研究库存。该评论概述了CEPI为应对全球健康挑战而建立的,迄今为止所取得的成就,并指出了未来几年的资金和协调重点。
更新日期:2020-04-17
down
wechat
bug